Depression, adherence and attrition from care in HIV-infected adults receiving antiretroviral therapy

Journal of Epidemiology and Community Health

Volumn 69, Issue 3, 2015, Pages 284-289

  Krumme, Alexis A ^a   Kaigamba, Felix ^b   Binagwaho, Agnes ^c   Murray, Megan B ^a,d   Rich, Michael L ^e,f   Franke, Molly F ^d,e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Ruhengeri Hospital   (Rwanda)

^c Ministry of Health of Rwanda   (Rwanda)

^d HARVARD MEDICAL SCHOOL   (United States)

^e PARTNERS IN HEALTH   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; DISEASE TREATMENT; HEALTH CARE; HUMAN IMMUNODEFICIENCY VIRUS; MENTAL HEALTH; QUALITY OF LIFE; RURAL AREA;

RWANDA;

ADULT; AGE DISTRIBUTION; AGED; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DEPRESSIVE DISORDER; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; MALE; MARRIAGE; MEDICATION COMPLIANCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PSYCHOLOGY; QUALITY OF LIFE; RURAL POPULATION; RWANDA; SEVERITY OF ILLNESS INDEX; SEX RATIO; SOCIAL STIGMA; SOCIAL SUPPORT; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DEPRESSIVE DISORDER; FEMALE; HIV INFECTIONS; HUMANS; MALE; MARITAL STATUS; MEDICATION ADHERENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RURAL POPULATION; RWANDA; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SOCIAL STIGMA; SOCIAL SUPPORT; YOUNG ADULT;

EID: 84924542245     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech-2014-204494     Document Type: Article

References (42)

1. Marcus M, Taghi Yasamy M, van Ommeren M, et al. Depression: A Global Public Health Concern. Secondary Depression: A Global Public Health Concern, 2012. http://www.who.int/mental_health/management/depression/who_paper_depression_ wfmh_2012.pdf
2. Bhatia R, Hartman C, Kallen MA, et al. Persons newly diagnosed with HIV infection are at high risk for depression and poor linkage to care: results from the Steps Study. AIDS Behav 2011;15:1161-70.
3. Lyketsos CG, Hoover DR, Guccione M, et al. Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Am J Psychiatry 1996;153:1430-7.
4. Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 2003;114:573-80.
5. Carrico AW, Riley ED, Johnson MO, et al. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization. J Acquir Immune Defic Syndr 2011;56:146-50.
6. Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999;13:1763-9.
7. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTIor PI-treated patients. HIV Clin Trials 2007;8:282-92.
8. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
9. Garcia de Olalla P, Knobel H, Carmona A, et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquired Immune Defic Syndr 2002;30:105-10.
10. Villes V, Spire B, Lewden C, et al. The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice. Antivir Ther 2007;12:1067-74.
11. Murphy K, Hoover DR, Shi Q, et al. Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. AIDS 2013;27:2413-23.
12. Cook JA, Grey D, Burke-Miller J, et al. Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women. AIDS Care 2006;18:93-100.
13. Greeson JM, Hurwitz BE, Llabre MM, et al. Psychological distress, killer lymphocytes and disease severity in HIV/AIDS. Brain Behav Immun 2008;22:901-11.
14. Evans DL, Ten Have TR, Douglas SD, et al. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry 2002;159:1752-9.
15. Leserman J, Petitto JM, Golden RN, et al. Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS. Am J Psychiatry 2000;157:1221-8.
16. Herbert TB, Cohen S. Depression and immunity: a meta-analytic review. Psychol Bull 1993;113:472-86.
17. Nurutdinova D, Chrusciel T, Zeringue A, et al. Mental health disorders and the risk of AIDS-defining illness and death in HIV-infected veterans. AIDS 2012;26:229-34.
18. Thomson DR, Rich ML, Kaigamba F, et al. Community-based accompaniment and psychosocial health outcomes in hiv-infected adults in Rwanda: a prospective study. AIDS Behav 2014;18:368-80.
19. Franke MF, Kaigamba F, Socci AR, et al. Improved retention associated with community-based accompaniment for antiretroviral therapy delivery in rural Rwanda. Clin Infect Dis 2013;56:1319-26.
20. National Guidelines for Comprehensive Care of People Living with HIV in Rwanda. Secondary National Guidelines for Comprehensive Care of People Living with HIV in Rwanda, 2011. http://rbc.gov.rw/library/sites/default/files/National%20guidelines% 20for%20comprehensive%20care%20of%20people%20living%20with%20hiv% 20in%20rwanda.pdf
21. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL). A measure of primary symptom dimensions. Mod Probl Pharmacopsychiatry 1974;7:79-110.
22. Epino HM, Rich ML, Kaigamba F, et al. Reliability and construct validity of three health-related self-report scales in HIV-positive adults in rural Rwanda. AIDS Care 2012;24:1576-83.
23. Mannheimer SB, Mukherjee R, Hirschhorn LR, et al. The CASE adherence index: a novel method for measuring adherence to antiretroviral therapy. AIDS Care 2006;18:853-61.
24. Weigel R, Hochgesang M, Brinkhof MW, et al. Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe, Malawi. BMC Infect Dis 2011;11:31.
25. Geng EH, Glidden DV, Emenyonu N, et al. Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. Trop Med Int Health 2010;15(Suppl 1):63-9.
26. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Secondary WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2007. http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf
27. Franke MF, Murray MB, Munoz M, et al. Food insufficiency is a risk factor for suboptimal antiretroviral therapy adherence among HIV-infected adults in urban Peru. AIDS Behav 2011;15:1483-9.
28. Broadhead WE, Gehlbach SH, de Gruy FV, et al. The Duke-UNC functional social support questionnaire. Measurement of social support in family medicine patients. Med Care 1988;26:709-23.
29. Wu AW, Revicki DA, Jacobson D, et al. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997;6:481-93.
30. Coates J, Swindale A, Bilinsky P. Household Food Insecurity Access Scale (HFIAS) for Measurement of Food Access: Indicator Guide. http://www.fantaproject.org/sites/ default/files/resources/HFIAS_ENG_v3_Aug07.pdf
31. Valeri L, Vanderweele TJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods 2013;18:137-50.
32. VanderWeele TJ. Marginal structural models for the estimation of direct and indirect effects. Epidemiology 2009;20:18-26.
33. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173-82.
34. Lima VD, Geller J, Bangsberg DR, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS 2007;21:1175-83.
35. Bolton P. Cross-cultural validity and reliability testing of a standard psychiatric assessment instrument without a gold standard. J Nerv Ment Dis 2001;189:238-42.
36. Wroe EB, Hedt-Gauthier BL, Franke MF, et al. Depression and patterns of self-reported adherence to antiretroviral therapy in Rwanda. Int J STD AIDS 2014. pii: 0956462414535206.
37. Bärnighausen T, Chaiyachati K, Chimbindi N, et al. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis 2011;11:942-51.
38. Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr 2007;45(Suppl 1):S14-18.
39. Elul B, Basinga P, Nuwagaba-Biribonwoha H, et al. High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda. PLoS ONE 2013;8:e53586.
40. Simoni JM, Wiebe JS, Sauceda JA, et al. A preliminary RCT of CBT-AD for adherence and depression among HIV-positive Latinos on the U.S.-Mexico border: the Nuevo Dia study. AIDS Behav 2013;17:2816-29.
41. Health Sector Policy: Government of Rwanda. Secondary Health Sector Policy: Government of Rwanda 2005. http://www.hrhresourcecenter.org/node/313
42. Edwards M, Byrd Quinlivan E, Bess K, et al. Implementation of PHQ-9 depression screening for HIV-infected patients in a real-world setting. J Assoc Nurses AIDS Care 2014;25:243-52.